Dark Blue Therapeutics

Pioneering the next generation of precision medicines to deliver a portfolio of transformative cancer therapies. Dark Blue Therapeutics is an innovative drug discovery biotechnology company based in Oxford, UK. We have assembled a highly experienced team, whose expertise spans the breadth of drug development from discovery to approval. This expertise has been gained over many years in the industry and draws from biotech, large pharmaceutical companies and investment management. Dark Blue leverages ground-breaking cancer biology insights, from Oxford University, to discover and develop innovative precision medicines that exploit novel vulnerabilities and dependencies. With this deep, proprietary understanding of target biology we match our precision medicines to molecularly defined patient populations to develop transformative, durable drugs that address critical unmet patient needs, delivering medicines that transform the outcomes for cancer patients. We work across a variety of biological mechanisms to identify and pursue only cancer targets that have the highest transformative potential.